These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 24912489)

  • 1. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
    Wheler JJ; Moulder SL; Naing A; Janku F; Piha-Paul SA; Falchook GS; Zinner R; Tsimberidou AM; Fu S; Hong DS; Atkins JT; Yelensky R; Stephens PJ; Kurzrock R
    Oncotarget; 2014 May; 5(10):3029-38. PubMed ID: 24912489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple gene aberrations and breast cancer: lessons from super-responders.
    Wheler JJ; Atkins JT; Janku F; Moulder SL; Yelensky R; Stephens PJ; Kurzrock R
    BMC Cancer; 2015 May; 15():442. PubMed ID: 26021831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
    Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
    Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
    Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
    J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
    Loi S; Michiels S; Baselga J; Bartlett JM; Singhal SK; Sabine VS; Sims AH; Sahmoud T; Dixon JM; Piccart MJ; Sotiriou C
    PLoS One; 2013; 8(1):e53292. PubMed ID: 23301057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
    Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
    Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
    Moroney JW; Schlumbrecht MP; Helgason T; Coleman RL; Moulder S; Naing A; Bodurka DC; Janku F; Hong DS; Kurzrock R
    Clin Cancer Res; 2011 Nov; 17(21):6840-6. PubMed ID: 21890452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
    Moulder S; Helgason T; Janku F; Wheler J; Moroney J; Booser D; Albarracin C; Morrow PK; Atkins J; Koenig K; Gilcrease M; Kurzrock R
    Ann Oncol; 2015 Jul; 26(7):1346-52. PubMed ID: 25878190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.
    Chen Z; Zheng Y; Cao W; Zhang Y; Zhao Z; Wang G; Zhao J; Cai S; Shao X; Huang J; Ye W; Huang Y; Li W; Huang X; Wu H; Wang X; Yin Y
    Cancer Med; 2019 Sep; 8(12):5544-5553. PubMed ID: 31385461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
    Treilleux I; Arnedos M; Cropet C; Wang Q; Ferrero JM; Abadie-Lacourtoisie S; Levy C; Legouffe E; Lortholary A; Pujade-Lauraine E; Bourcier AV; Eymard JC; Spaeth D; Bachelot T
    Ann Oncol; 2015 Jan; 26(1):120-125. PubMed ID: 25361980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K/AKT/mTOR.
    Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
    Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
    Rodrigues HV; Ke D; Lim J; Stephen B; Bellido J; Janku F; Zinner R; Tsimberidou A; Hong D; Piha-Paul S; Fu S; Naing A; Subbiah V; Karp D; Falchook G; Kurzrock R; Wheler J
    Invest New Drugs; 2015 Jun; 33(3):700-9. PubMed ID: 25902899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study.
    Liu Y; Zhang X; Liu J; Hou G; Zhang S; Zhang J
    Tumour Biol; 2014 Feb; 35(2):1275-86. PubMed ID: 24014089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
    Basho RK; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Herbrich SM; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Ibrahim NK; Murray JL; Koenig KB; Hong D; Subbiah V; Kurzrock R; Janku F; Moulder SL
    JAMA Oncol; 2017 Apr; 3(4):509-515. PubMed ID: 27893038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.
    Morrow PK; Wulf GM; Ensor J; Booser DJ; Moore JA; Flores PR; Xiong Y; Zhang S; Krop IE; Winer EP; Kindelberger DW; Coviello J; Sahin AA; Nuñez R; Hortobagyi GN; Yu D; Esteva FJ
    J Clin Oncol; 2011 Aug; 29(23):3126-32. PubMed ID: 21730275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.
    Trédan O; Treilleux I; Wang Q; Gane N; Pissaloux D; Bonnin N; Petit T; Cretin J; Bonichon-Lamichhane N; Priou F; Lavau-Denes S; Mari V; Freyer G; Lebrun D; Alexandre J; Ray-Coquard I
    Target Oncol; 2013 Dec; 8(4):243-51. PubMed ID: 23238879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
    Baselga J; Campone M; Piccart M; Burris HA; Rugo HS; Sahmoud T; Noguchi S; Gnant M; Pritchard KI; Lebrun F; Beck JT; Ito Y; Yardley D; Deleu I; Perez A; Bachelot T; Vittori L; Xu Z; Mukhopadhyay P; Lebwohl D; Hortobagyi GN
    N Engl J Med; 2012 Feb; 366(6):520-9. PubMed ID: 22149876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.